Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RXRα:PPARα heterodimer is a nuclear receptor complex formed by the association of Retinoid X receptor alpha (RXRα) and Peroxisome proliferator-activated receptor alpha (PPARα) [1.1.1]. This heterodimer acts as a ligand-dependent transcription factor that binds to specific DNA sequences known as Peroxisome Proliferator Response Elements (PPREs) to regulate the expression of genes involved in lipid and glucose metabolism [1.2.2]. It is considered a "permissive" heterodimer because it can be activated by ligands of either partner, such as fibrates for PPARα or rexinoids for RXRα, which often exhibit synergistic effects [1.3.2]. Biologically, the complex is essential for fatty acid oxidation, particularly in the liver and heart, and plays a significant role in modulating systemic inflammation and energy balance [1.3.1]. Dysregulation of this pathway is linked to metabolic diseases such as dyslipidemia, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) [1.2.1]. Consequently, the RXRα:PPARα heterodimer is a major therapeutic target for drugs aimed at lowering triglycerides and improving insulin sensitivity. However, clinical use of its agonists is associated with safety concerns, including potential hepatotoxicity and muscle-related toxicities like rhabdomyolysis [1.4.1, 1.4.2].
The RXRα:PPARα heterodimer functions as a ligand-activated transcription factor that binds to Peroxisome Proliferator Response Elements (PPREs) in the promoter regions of target genes. Upon binding of agonists to either the PPARα or RXRα subunit, the complex undergoes a conformational change that facilitates the release of corepressors and the recruitment of coactivators, thereby initiating the transcription of genes primarily involved in fatty acid oxidation, lipid transport, and energy homeostasis [1.1.1, 1.2.1].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoid X receptor alpha:Peroxisome proliferator-activated receptor alpha heterodimer (RXRα:PPARα).